0001586939-14-000004.txt : 20140505
0001586939-14-000004.hdr.sgml : 20140505
20140505174855
ACCESSION NUMBER: 0001586939-14-000004
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140501
FILED AS OF DATE: 20140505
DATE AS OF CHANGE: 20140505
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: FATE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001434316
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 3535 GENERAL ATOMICS COURT
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858.875.1803
MAIL ADDRESS:
STREET 1: 3535 GENERAL ATOMICS COURT
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Flynn Peter D
CENTRAL INDEX KEY: 0001586939
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36076
FILM NUMBER: 14814771
MAIL ADDRESS:
STREET 1: C/O FATE THERAPEUTICS, INC.
STREET 2: 3535 GENERAL ATOMICS COURT, SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2014-05-01
0
0001434316
FATE THERAPEUTICS INC
FATE
0001586939
Flynn Peter D
C/O FATE THERAPEUTICS, INC.
3535 GENERAL ATOMICS COURT, SUITE 200
SAN DIEGO
CA
92121
0
1
0
0
See remarks
Common Stock
2014-05-01
4
M
0
6925
1.63
A
13656
D
Common Stock
2014-05-01
4
M
0
1100
1.63
A
14756
D
Common Stock
2014-05-01
4
M
0
422
1.37
A
15178
D
Common Stock
2014-05-01
4
S
0
9793
7.0662
D
5385
D
Stock Option (right to buy)
1.63
2014-05-01
4
M
0
6925
D
2022-02-08
Common Stock
6925
30816
D
Stock Option (right to buy)
1.63
2014-05-01
4
M
0
1100
D
2022-02-08
Common Stock
1100
25300
D
Stock Option (right to buy)
1.37
2014-05-01
4
M
0
422
D
2022-07-23
Common Stock
422
19872
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.19, inclusive.
The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on May 30, 2012 and 1/48th of the shares each month thereafter such that this option is fully exercisable on May 30, 2015. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
Not applicable.
The shares subject to this option shall vest and become exercisable in 24 equal monthly installments beginning on the date one month after the completion of the Issuer's initial public offering. This option is subject to accelerated vesting upon a change of control of the Issuer after the completion of the Issuer's initial public offering.
The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 3, 2012 such that this option is fully exercisable on July 3, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.
Senior Vice President, Early Program Development
/s/ Cindy R. Tahl, as Attorney-in-Fact
2014-05-05